Boost for medical research institutes
Print Edition
The first drug manufacturing license for medical research institutes in China was issued by Shanghai authorities yesterday, lifting the restrictions imposed on such drug research organizations from participating in medicine bidding and procurement.
Some provinces require drug research institutes to obtain the license before they are allowed to participate in bidding and procurement, leaving them unable to enjoy some preferential policies, the Shanghai Drug Administration said.
The first license was issued to Anbison Lab.
“The reform will stimulate the innovation vitality of biomedicine companies,” said Zhang Qing, deputy director of the administration.
Applications for drug manufacturing license from nine drug research institutes in Shanghai are being reviewed, according to the administration.
- About Us
- |
- Terms of Use
- |
-
RSS - |
- Privacy Policy
- |
- Contact Us
- |
- Shanghai Call Center: 962288
- |
- Tip-off hotline: 52920043
- 沪ICP证：沪ICP备05050403号-1
- |
- 互联网新闻信息服务许可证：31120180004
- |
- 网络视听许可证：0909346
- |
- 广播电视节目制作许可证：沪字第354号
- |
- 增值电信业务经营许可证：沪B2-20120012
Copyright © 1999- Shanghai Daily. All rights reserved.Preferably viewed with Internet Explorer 8 or newer browsers.
